Mineralys Therapeutics, Inc.
NASDAQ:MLYSBiotechnology
+$0.37 today
- Market cap
- $1.22B
- Beta
- 0.56
- P/E (TTM)
- -13.9
- EPS (TTM)
- -$1.83
Volume 1.39M
Average 1.48M
MLYS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Mineralys Therapeutics, Inc.NASDAQ: MLYS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $241.07M (cash outflow) rose 457.1% year over year, ahead of the +83.2% change in trailing-twelve-month net income. Sequentially, it rose 512.8% from the prior quarter. Over 3 fiscal years it compounded at +73.1% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$157.31M (+1.7%) for the fiscal year ending Dec 2026, a step up from the -13.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$241.07M+512.8% QoQ
- Last fiscal yearDec 2025
- -$154.65M-13.0% YoY
- LTMJun 2026
- -$349.58M+83.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +457.1% | +28.2% | -428.9 pp |
| 1 year | -13.0% | +1.7% | +14.7 pp |
| 3-year CAGR | +73.1% | -12.0% | -85.1 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (154.65M) USD
- Year-over-year change
- +13.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (154.65M) | +13.0% |
| FY2024 | 2024-12-31 | (177.81M) | -147.3% |
| FY2023 | 2023-12-31 | (71.9M) | -141.3% |
| FY2022 | 2022-12-31 | (29.8M) | -53.5% |
| FY2021 | 2021-12-31 | (19.41M) | — |
Net Income vs competitors
How MLYS compares with its peers on the latest reported figures
- MLYS's LTM Jun 2026 net income of $349.58M is the 2nd largest of the 7 companies compared; the peer median is $88.59M.
- Its year-over-year change of +83.2% is the 3rd highest of 7, against a peer median of +47.6%.
- Over three fiscal years its annual growth of +73.1% compares with a peer median of +14.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $401.9M | +84.1% | +49.8% | — | |
| LTM Jun 2026 | $349.58M | +83.2% | +73.1% | — | |
| LTM Sep 2026 | $146.22M | +65.1% | -57.4% | 22.5% | |
| LTM Mar 2026 | $122.54M | -335.9% | +4.5% | 612.7% | |
| LTM Mar 2026 | $54.64M | -17.6% | +16.2% | 167.0% | |
| LTM Mar 2026 | $39.95M | +162.9% | +13.7% | — | |
| LTM Mar 2026 | $35.1M | +30.0% | +33.8% | — | |
| Peer median (excluding MLYS) | $88.59M | +47.6% | +14.9% | 167.0% | |
Competitors are the stored peer set for MLYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (19.41M) | (29.8M) | (71.9M) | (177.81M) | (154.65M) |
| Depreciation & Amortization | 0 | 0 | 0 | 43K | 59K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 80K | 455K | 5.06M | 11.34M | 19.32M |
| Change in Working Capital | 4.09M | 772K | (7.47M) | 9.52M | 2.73M |
| Accounts Receivables | 0 | 0 | (355K) | 424K | (166K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 4.09M | 772K | (7.12M) | 9.1M | 2.9M |
| Other Non-Cash Items | 684K | (649K) | (6.87M) | (9.41M) | (9.88M) |
| Operating Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.31M) | (142.42M) |
| Capital Expenditures | 0 | 0 | 0 | (96K) | (15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (71.76M) | (347.97M) | (373.45M) | (814.74M) |
| Sales of Investments | 0 | 50M | 187.5M | 488.5M | 425M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (21.76M) | (160.47M) | 114.96M | (389.75M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 23.81M | 0 | 202.99M | 116.06M | 591M |
| Common Stock Repurchased | 0 | (1.63M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 258K | 83K | 0 |
| Financing Cash Flow | 23.81M | 128.02M | 203.25M | 116.14M | 591M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 9.25M | 77.04M | (38.4M) | 64.79M | 58.83M |
| Free Cash Flow | (14.56M) | (29.22M) | (81.17M) | (166.41M) | (142.43M) |
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
Intrinsic Alpha fair value
Locked
Current Price
$13.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.